Oncogenic Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations, which occur in over 90% of human PDAC, are the dominant driver for tumor progression and play a critical role in reprogramming metabolism [2]. This evidence concerns the gene KRAS and neoplasm.